This application for re-selection as a Diabetes TrialNet Clinical Center consists of a leadership statement outlining our perspective and approach to address TrialNet's current challenges. It also describes our Clinical Center's current and planned activities to accomplish TrialNet's mission including innovative approaches to collaboratively and efficiently achieving our overarching goal - delaying and preventing the onset of clinical type 1 diabetes. The TrialNet Northwest Clinical Center recruitment region encompasses Alaska, Washington, Oregon, Idaho, and Montana. We work with more than a dozen Affiliate sites, local and regional T1D advocacy groups and diabetes health care providers to assure that those with T1D are aware that their relatives are at risk for disease and that screening along with the possibility of prevention trials through TrialNet are available. We also have significant recruitment efforts using digital media, including the use of websites, Facebook, Twitter, to convey information and foster discussion. More than 7500 individuals in our region have been screened for risk. TrialNet Northwest Clinical Center team members are active participants and are in leadership roles in the TrialNet network. We plan to work collaboratively within the new TrialNet structure to prevent or delay type 1 diabetes.

Public Health Relevance

TrialNet is an international network with the primary aim of delaying or preventing type 1 diabetes. This is an application from Dr. Greenbaum and the Benaroya Research Institute to continue as the Type 1 Diabetes TrialNet Northwest Clinical Center and conduct clinical trials to stop type 1 diabetes. Our recruitment region encompasses Alaska, Washington, Oregon, Idaho, and Montana.

Agency
National Institute of Health (NIH)
Type
Research Project--Cooperative Agreements (U01)
Project #
2U01DK061034-13
Application #
8776647
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Leschek, Ellen W
Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Benaroya Research Institute at Virginia Mason
Department
Type
DUNS #
City
Seattle
State
WA
Country
United States
Zip Code
98101
Ismail, Heba M; White, Kama S; Krischer, Jeffrey P et al. (2015) First test effect in intravenous glucose tolerance testing. Pediatr Diabetes 16:129-37
Orban, Tihamer; Beam, Craig A; Xu, Ping et al. (2014) Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline. Diabetes 63:3449-57
Orban, Tihamer; Bundy, Brian; Becker, Dorothy J et al. (2014) Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 37:1069-75
Arif, Sefina; Leete, Pia; Nguyen, Vy et al. (2014) Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. Diabetes 63:3835-45
Beam, Craig A; Gitelman, Stephen E; Palmer, Jerry P et al. (2014) Recommendations for the definition of clinical responder in insulin preservation studies. Diabetes 63:3120-7
Pescovitz, Mark D; Greenbaum, Carla J; Bundy, Brian et al. (2014) B-lymphocyte depletion with rituximab and *-cell function: two-year results. Diabetes Care 37:453-9
Kroll, Jing Lu; Beam, Craig; Li, Shaobing et al. (2013) Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes. J Clin Virol 57:115-9
Krischer, Jeffrey P; Type 1 Diabetes TrialNet Study Group (2013) The use of intermediate endpoints in the design of type 1 diabetes prevention trials. Diabetologia 56:1919-24
Loechelt, Brett J; Boulware, David; Green, Michael et al. (2013) Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolate mofetil. Clin Infect Dis 56:248-54
Sosenko, Jay M; Skyler, Jay S; Palmer, Jerry P et al. (2013) The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care 36:2615-20

Showing the most recent 10 out of 17 publications